• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Commentary on Lahiri et al. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV.关于拉希里等人的评论：感染艾滋病毒女性改用整合酶抑制剂或替诺福韦艾拉酚胺后的体重及体重指数变化
J AIDS HIV Treat. 2021;3(2):21-23. doi: 10.33696/AIDS.3.016.
2
Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.在美国，接受单片制剂达芦那韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺或比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺治疗的 HIV-1 感染者中体重指数增加和体重增加的情况。
Curr Med Res Opin. 2022 Feb;38(2):287-298. doi: 10.1080/03007995.2021.2007006. Epub 2021 Dec 7.
3
Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF.病例报告：换回依非韦伦/恩曲他滨/替诺福韦酯后，整合酶抑制剂和替诺福韦艾拉酚胺相关体重增加的逆转
Open Forum Infect Dis. 2021 Aug 2;8(8):ofab403. doi: 10.1093/ofid/ofab403. eCollection 2021 Aug.
4
Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.抗逆转录病毒药物转换为整合酶抑制剂或替诺福韦艾拉酚胺治疗后的体重增加比较。
Infection. 2022 Apr;50(2):407-412. doi: 10.1007/s15010-021-01687-6. Epub 2021 Aug 27.
5
One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences ≥10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor.在荷兰，每10名病毒得到抑制的艾滋病毒感染者中，就有1人在换用替诺福韦艾拉酚胺和/或整合酶链转移抑制剂后体重增加≥10%。
Open Forum Infect Dis. 2022 Jun 10;9(7):ofac291. doi: 10.1093/ofid/ofac291. eCollection 2022 Jul.
6
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.一项多中心、开放标签、3b 期、随机试验：在 HIV-1 病毒学抑制的 60 岁及以上人群中，将包含富马酸替诺福韦二吡呋酯的方案转换为艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺单片复方制剂方案时，对骨矿物质密度的影响。
Lancet HIV. 2019 Oct;6(10):e655-e666. doi: 10.1016/S2352-3018(19)30195-X.
7
Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.在 HIV-1 感染患者中，从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺治疗的结果：日本的一项真实世界研究。
HIV Med. 2021 Jul;22(6):457-466. doi: 10.1111/hiv.13061. Epub 2021 Mar 15.
8
Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV.整合酶抑制剂和替诺福韦艾拉酚胺对 HIV 感染者体重增加的影响。
Curr Opin HIV AIDS. 2021 May 1;16(3):148-151. doi: 10.1097/COH.0000000000000680.
9
Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group.在接受过抗逆转录病毒治疗的人群中，从富马酸替诺福韦二吡呋酯转换为富马酸替诺福韦艾拉酚胺后，体重和身体质量指数增加。
Int J STD AIDS. 2021 May;32(6):570-577. doi: 10.1177/0956462420983699. Epub 2021 Feb 20.
10
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.在病毒学抑制的 HIV 成人中，长效卡替拉韦加利匹韦林转换治疗与继续固定剂量比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺相比的疗效、安全性和耐受性，12 个月结果（SOLAR）：一项随机、开放标签、3b 期、非劣效性试验。
Lancet HIV. 2023 Sep;10(9):e566-e577. doi: 10.1016/S2352-3018(23)00136-4. Epub 2023 Aug 8.

引用本文的文献

1
Cardiovascular risk factors and cognitive performance among people living with HIV: cross-sectional study in the country of Georgia.艾滋病毒感染者的心血管危险因素与认知能力：格鲁吉亚的横断面研究
BMJ Open. 2025 Mar 24;15(3):e090918. doi: 10.1136/bmjopen-2024-090918.

本文引用的文献

1
2021 Alzheimer's disease facts and figures.2021 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2021 Mar;17(3):327-406. doi: 10.1002/alz.12328. Epub 2021 Mar 23.
2
Epidemiology Informs Randomized Clinical Trials of Cognitive Impairments and Late-Onset, Sporadic Dementias.流行病学为认知障碍和晚发性散发性痴呆的随机临床试验提供信息。
J Neurol Neuromedicine. 2018;3(5):13-18. doi: 10.29245/2572.942x/2018/5.1220.
3
Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV.换用整合酶抑制剂或替诺福韦艾拉酚胺后 HIV 感染者女性的体重和身体质量指数变化。
AIDS Res Hum Retroviruses. 2021 Jun;37(6):461-467. doi: 10.1089/AID.2020.0197. Epub 2021 Jan 12.
4
Metabolic Changes Associated With the Use of Integrase Strand Transfer Inhibitors Among Virally Controlled Women.整合酶链转移抑制剂在病毒控制的女性中使用相关的代谢变化。
J Acquir Immune Defic Syndr. 2020 Nov 1;85(3):355-362. doi: 10.1097/QAI.0000000000002447.
5
Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.在美国和加拿大的一个大型观察性队列中，与非核苷类逆转录酶抑制剂或蛋白酶抑制剂相比，初治 HIV 感染者开始使用整合酶抑制剂后体重增加。
J Int AIDS Soc. 2020 Apr;23(4):e25484. doi: 10.1002/jia2.25484.
6
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.抗逆转录病毒治疗起始后体重增加：随机对照临床试验中的危险因素。
Clin Infect Dis. 2020 Sep 12;71(6):1379-1389. doi: 10.1093/cid/ciz999.
7
Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women.女性使用整合酶抑制剂与体重增加相关。
Clin Infect Dis. 2020 Jul 27;71(3):593-600. doi: 10.1093/cid/ciz853.
8
Adiposity is related to cerebrovascular and brain volumetry outcomes in the RUN DMC study.肥胖与 RUN DMC 研究中的脑血管和脑容积测量结果有关。
Neurology. 2019 Aug 27;93(9):e864-e878. doi: 10.1212/WNL.0000000000008002. Epub 2019 Jul 30.
9
Obesity: global epidemiology and pathogenesis.肥胖症：全球流行病学和发病机制。
Nat Rev Endocrinol. 2019 May;15(5):288-298. doi: 10.1038/s41574-019-0176-8.
10
Progressive increases in fat mass occur in adults living with HIV on antiretroviral therapy, but patterns differ by sex and anatomic depot.在接受抗逆转录病毒疗法的艾滋病毒感染者中，脂肪量逐渐增加，但性别和解剖部位的不同模式存在差异。
J Antimicrob Chemother. 2019 Apr 1;74(4):1028-1034. doi: 10.1093/jac/dky551.

Commentary on Lahiri et al. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV.

作者信息

Macaluso Francesca, Gustafson Deborah R

机构信息

Department of Medicine, State University of New York at Downstate Health Sciences University, Brooklyn NY, United States.

Department of Neurology, Section for NeuroEpidemiology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA.

出版信息

J AIDS HIV Treat. 2021;3(2):21-23. doi: 10.33696/AIDS.3.016.

DOI:10.33696/AIDS.3.016
PMID:34291233
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8291731/
Abstract
摘要